Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- T-cell Exhaustion in Myeloma
T-cell Exhaustion in Myeloma
According to the research below, myeloma patients should consider that T-cell exhaustion can have a dramatic effect on the success or failure of the therapy they undergo.
MM survivors have known, at least intuitively, that successive rounds of chemotherapy, year in and year out, weaken their immune system. As more cytotoxic therapies are developed for MMers, sequencing of the therapies is turning out to be as important to the life of the MM survivor as the therapy itself.
ChatGPT said:
T-cell exhaustion is a significant issue in multiple myeloma (MM), particularly as the disease progresses or after multiple lines of therapy. Several myeloma therapies have been shown or are strongly associated with T-cell exhaustion—a state in which T-cells lose their ability to proliferate and effectively kill tumor cells due to chronic antigen exposure and immunosuppressive signals.
Here’s a summary of the main therapy classes linked to T-cell exhaustion:
🔴 1. CAR-T Cell Therapy
-
Mechanism: CAR-T involves engineering a patient’s T-cells to target BCMA or other myeloma antigens. These cells expand rapidly and kill MM cells, but prolonged antigen stimulation and the tumor microenvironment can exhaust them.
-
Markers of exhaustion: Increased expression of PD-1, LAG-3, TIM-3, and TIGIT after infusion.
-
Clinical impact: T-cell exhaustion contributes to relapse after initial response and limited durability of CAR-T therapy (e.g., ide-cel, cilta-cel).
🔴 2. Bispecific Antibodies (e.g., BCMA x CD3 bispecifics)
-
Mechanism: Continually recruit and engage T-cells against MM cells. While potent initially, persistent activation can drive exhaustion.
-
Evidence:
-
Chronic exposure to BCMA/CD3 bispecifics like teclistamab has been linked to reduced T-cell proliferative capacity and upregulation of exhaustion markers.
-
This is especially seen in patients who relapse after bispecific therapy.
-
🟠 3. Lenalidomide and Pomalidomide (IMiDs)
-
Mechanism: IMiDs have immunostimulatory effects (e.g., enhancing IL-2, T-cell and NK-cell activation), but chronic use may paradoxically promote exhaustion over time.
-
Evidence:
-
Long-term exposure can contribute to T-cell dysfunction in relapsed/refractory patients, especially when used continuously as maintenance.
-
May also enhance PD-1/PD-L1 pathway, a key regulator of T-cell exhaustion.
-
🟠 4. Proteasome Inhibitors (e.g., Bortezomib, Carfilzomib)
-
Mechanism: Not directly immunosuppressive to T-cells, but repeated use can alter the immune microenvironment.
-
Evidence:
-
Some data suggest bortezomib reduces T-cell numbers and function, indirectly contributing to exhaustion, particularly in heavily pre-treated patients.
-
🟡 5. Corticosteroids (e.g., Dexamethasone)
-
Mechanism: Profound immunosuppressive effects; induce T-cell apoptosis, impair activation and cytokine production.
-
Evidence:
-
Chronic use strongly impairs T-cell function and promotes immune senescence/exhaustion.
-
Dexamethasone is particularly detrimental to CD8+ cytotoxic T-cell function over time.
-
🔴 6. High Tumor Burden and Chronic Antigen Exposure
-
Not a therapy, but chronic exposure to MM antigens from persistent or residual disease also contributes significantly to exhaustion, even in the absence of immune-modulating drugs.
🧬 Common Features of Exhausted T-cells in Myeloma:
-
Upregulation of inhibitory receptors: PD-1, LAG-3, TIM-3, TIGIT
-
Loss of cytokine production (e.g., IFN-γ, IL-2)
-
Impaired proliferation and cytotoxicity
-
Epigenetic changes that “lock in” exhaustion
🧠 Summary Table:
| Therapy Class | T-cell Exhaustion Risk | Mechanism |
|---|---|---|
| CAR-T Cell Therapy | High | Chronic stimulation; immunosuppressive microenvironment |
| Bispecific Antibodies | High | Continuous T-cell engagement and activation |
| IMiDs (Len, Pom) | Moderate | Chronic immune stimulation; PD-1 upregulation |
| Proteasome Inhibitors | Low–Moderate | Indirect via TME and immune suppression |
| Corticosteroids | High | Direct T-cell suppression and apoptosis |
I am a long-term MM survivor. I’ve learned the hard way that conventional oncology focuses on FDA-approved therapies. Unfortunately, at this point, there are few, if any, conventional therapies that can reverse T-cell exhaustion.
Email me at David.PeopleBeatingCancer@gmail.com to learn more about managing MM with both conventional and non-conventional therapies.
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
“The discussion focused on the sequencing of BCMA-targeted therapies in multiple myeloma, highlighting how prior treatment with BCMA agents—such as bispecific antibodies or antibody-drug conjugates—can impact the efficacy of subsequent CAR T-cell therapy.
Clinical trials leading to the approval of these agents excluded patients previously exposed to other BCMA therapies, but real-world data has shown that prior use, particularly within 6 months before CAR T, may reduce CAR T efficacy.
Possible mechanisms include BCMA downregulation or loss and T-cell exhaustion, underscoring the importance of strategic sequencing.
Experts emphasized that current evidence supports administering CAR T therapy before bispecifics when possible. Patients who respond to CAR T therapy often retain sensitivity to BCMA-targeted bispecifics upon relapse, with studies showing progression-free survival exceeding 18 months in such scenarios.
In contrast, outcomes are generally worse when patients receive bispecific antibodies first, then attempt CAR T. This pattern is further supported by real-world data and emerging consensus guidelines that recommend CAR T first, when access and patient condition allow.
Nonetheless, there are situations where bispecifics may precede CAR T therapy. These include limited access to CAR T, urgent disease progression requiring immediate treatment, or patient preference due to logistical challenges, such as lack of caregiver support.
In these cases, bispecifics may be used as “bridging” or “holding” therapy, though ideally not before T-cell collection to avoid compromising CAR T product quality. A recent consensus paper clarified terminology around “holding therapy” (before apheresis) and “bridging therapy” (between apheresis and infusion), recommending bispecifics like talquetamab primarily in the bridging phase.
This evolving body of real-world evidence continues to guide clinical decisions in sequencing immunotherapies for optimal outcomes in relapsed/refractory multiple myeloma.”
Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
The incidence of multiple myeloma (MM), a bone marrow (BM) resident hematological malignancy, is increasing globally. The disease has substantial morbidity and mortality and remains largely incurable.
Clinical studies show that autologous stem cell transplantation (ASCT) remains efficacious in eligible patients, providing a progression-free survival (PFS) benefit beyond novel therapies alone.
Conventionally, improved PFS after ASCT is attributed to cytoreduction from myeloablative chemotherapy. However, ASCT results in immune effects beyond cytoreduction, including
- inflammation,
- lymphodepletion,
- T cell priming via immunogenic cell death,
- and disruption of the tumor BM microenvironment.
In fact, a small subset of patients achieve very long-term control of disease post-ASCT, akin to that seen in the context of immune-mediated graft-vs.-myeloma effects after allogeneic SCT. These clinical observations coupled with recent definitive studies in mice demonstrating that progression after ASCT represents immune escape as a consequence of T cell exhaustion, highlight the potential for new immunotherapy maintenance strategies to prevent myeloma progression following consolidation with ASCT.
T-cell exhaustion in myeloma T-cell exhaustion in myeloma T-cell exhaustion in myeloma